Devyser secures SEK 8.9M five-year tender and strengthens Italian position
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and...
Read More
For many laboratories, CFTR testing is not an occasional add-on. It is part of a routine,...
Read More
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More